These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 30134055)

  • 21. Intranigral administration of substance P receptor antagonist attenuated levodopa-induced dyskinesia in a rat model of Parkinson's disease.
    Yang X; Zhao H; Shi H; Wang X; Zhang S; Zhang Z; Zu J; Zhang W; Shen X; Cui G; Hua F
    Exp Neurol; 2015 Sep; 271():168-74. PubMed ID: 26001615
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatments for Parkinson disease--past achievements and current clinical needs.
    Poewe W
    Neurology; 2009 Feb; 72(7 Suppl):S65-73. PubMed ID: 19221317
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Levodopa in the early treatment of Parkinson's disease.
    Murata M
    Parkinsonism Relat Disord; 2009 Jan; 15 Suppl 1():S17-20. PubMed ID: 19131036
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Development of dyskinesias induced by treatment for Parkinson's disease: potential role of first exposure to L-DOPA (or phenomenon of priming)].
    Damier P; Tremblay L; Féger J; Hirsch EC
    Rev Neurol (Paris); 2000 Mar; 156(3):224-35. PubMed ID: 10740093
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The hidden sister of motor fluctuations in Parkinson's disease: A review on nonmotor fluctuations.
    Martínez-Fernández R; Schmitt E; Martinez-Martin P; Krack P
    Mov Disord; 2016 Aug; 31(8):1080-94. PubMed ID: 27431515
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MRI of Motor and Nonmotor Therapy-Induced Complications in Parkinson's Disease.
    Donzuso G; Agosta F; Canu E; Filippi M
    Mov Disord; 2020 May; 35(5):724-740. PubMed ID: 32181946
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Opioids and motor complications in Parkinson's disease.
    Samadi P; Bédard PJ; Rouillard C
    Trends Pharmacol Sci; 2006 Oct; 27(10):512-7. PubMed ID: 16908075
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Treatment and prognosis of juvenile parkinsonism--L-dopa responsiveness].
    Takubo H
    Nihon Rinsho; 1997 Jan; 55(1):101-5. PubMed ID: 9014430
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease.
    Bastide MF; Meissner WG; Picconi B; Fasano S; Fernagut PO; Feyder M; Francardo V; Alcacer C; Ding Y; Brambilla R; Fisone G; Jon Stoessl A; Bourdenx M; Engeln M; Navailles S; De Deurwaerdère P; Ko WK; Simola N; Morelli M; Groc L; Rodriguez MC; Gurevich EV; Quik M; Morari M; Mellone M; Gardoni F; Tronci E; Guehl D; Tison F; Crossman AR; Kang UJ; Steece-Collier K; Fox S; Carta M; Angela Cenci M; Bézard E
    Prog Neurobiol; 2015 Sep; 132():96-168. PubMed ID: 26209473
    [TBL] [Abstract][Full Text] [Related]  

  • 30. L-DOPA-induced dyskinesias, motor fluctuations and health-related quality of life: the COPARK survey.
    Perez-Lloret S; Negre-Pages L; Damier P; Delval A; Derkinderen P; Destée A; Meissner WG; Tison F; Rascol O;
    Eur J Neurol; 2017 Dec; 24(12):1532-1538. PubMed ID: 28940893
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group.
    Parkinson Study Group
    JAMA; 2000 Oct; 284(15):1931-8. PubMed ID: 11035889
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Therapeutic strategies to prevent motor complications in Parkinson's disease.
    Kieburtz K
    J Neurol; 2008 Aug; 255 Suppl 4():42-5. PubMed ID: 18821085
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long term motor complications of levodopa: clinical features, mechanisms, and management strategies.
    Thanvi BR; Lo TC
    Postgrad Med J; 2004 Aug; 80(946):452-8. PubMed ID: 15299154
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Novel formulations and modes of delivery of levodopa.
    Poewe W; Antonini A
    Mov Disord; 2015 Jan; 30(1):114-20. PubMed ID: 25476691
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study.
    Bracco F; Battaglia A; Chouza C; Dupont E; Gershanik O; Marti Masso JF; Montastruc JL;
    CNS Drugs; 2004; 18(11):733-46. PubMed ID: 15330687
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Four pioneers of L-dopa treatment: Arvid Carlsson, Oleh Hornykiewicz, George Cotzias, and Melvin Yahr.
    Lees AJ; Tolosa E; Olanow CW
    Mov Disord; 2015 Jan; 30(1):19-36. PubMed ID: 25488030
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Social and economic cost of L-Dopa-induced dyskinesias in patients with Parkinson's disease].
    Maurel F; Lilliu H; Le Pen C
    Rev Neurol (Paris); 2001 May; 157(5):507-14. PubMed ID: 11438770
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of motor symptoms in advanced Parkinson's disease: a practical approach.
    Maranis S; Tsouli S; Konitsiotis S
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Dec; 35(8):1795-807. PubMed ID: 21645577
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Use of metabotropic glutamate 5-receptor antagonists for treatment of levodopa-induced dyskinesias.
    Rascol O; Fox S; Gasparini F; Kenney C; Di Paolo T; Gomez-Mancilla B
    Parkinsonism Relat Disord; 2014 Sep; 20(9):947-56. PubMed ID: 24951359
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intrajejunal levodopa infusion in Parkinson's disease: a pilot multicenter study of effects on nonmotor symptoms and quality of life.
    Honig H; Antonini A; Martinez-Martin P; Forgacs I; Faye GC; Fox T; Fox K; Mancini F; Canesi M; Odin P; Chaudhuri KR
    Mov Disord; 2009 Jul; 24(10):1468-74. PubMed ID: 19425079
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.